Drugs Home > Carfilzomib

Carfilzomib is given intravenously once a day for two days in a row every week to help treat multiple myeloma. This prescription drug is reserved for use in people whose cancer has progressed or become worse after at least two other chemotherapy treatments. Most people who receive this medicine will develop some type of side effect, such as fatigue, anemia, or nausea.


What Is Carfilzomib?

Carfilzomib (Kyprolis™) is a prescription medication approved to treat multiple myeloma, a cancer of the plasma cells, a type of white blood cell found in the bone marrow. It is for use in people whose cancer progressed after treatment with at least two other medications. Carfilzomib belongs to a group of medicines known as proteasome inhibitors.
(Click What Is Carfilzomib Used For? for more information on this topic, including possible off-label uses.)

Are There Side Effects?

Just like any chemotherapy medicine, carfilzomib can cause side effects, some of which can be significant and potentially serious. In fact, most people will experience some type of side effect during treatment. Talk with your healthcare provider about ways to prevent or lessen reactions to this drug.
Possible side effects of carfilzomib include but are not limited to:
  • Fatigue
  • Anemia (low red blood cell counts)
  • Nausea
  • Low platelet counts.
(Click Carfilzomib Side Effects to learn more, including potentially serious side effects you should report immediately to your healthcare provider.)
Written by/reviewed by:
Last reviewed by: Kristi Monson, PharmD;
Last updated/reviewed:
List of references (click here):
Other Articles in This eMedTV Presentation

Topics & Medications


Related Channels

eMedTV Links
Copyright © 2006-2020 Clinaero, Inc.

eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.

This site complies with the HONcode standard for trustworthy health information:
verify here.